Amal

Quick links to important sections

Amal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amal

What is Amal and How is it Classified?

Amal is a medicine containing the active ingredient Ondansetron, a synthetic organic compound that is formally classified as an Antiemetic. Its specific grouping is that of a Selective 5-HT3 Antagonist, defining its targeted physiological mechanism designed for its action on sickness pathways. The mechanism involves the precise blocking of the chemical messenger serotonin (5-HT) from activating specific 5-HT3 receptors in the body. This focused approach differentiates it from broader anti-nausea medications, making it a key agent in managing acute sickness signals.

Composition, Forms, and General Therapeutic Purpose

The medicine is a single-ingredient product, containing only Ondansetron within its various formulations. It is manufactured in several dosage forms, facilitating various routes of administration. These include the standard film-coated tablet, a liquid oral solution, and an injectable solution designed for both intravenous (IV) and intramuscular (IM) use. A distinctive feature is the availability of the Orally Disintegrating Tablet (ODT), a unique freeze-dried form of the ondansetron base designed to dissolve rapidly without water, offering an alternative for patients who cannot easily swallow a tablet. The general therapeutic purpose of Amal is to serve as a potent antiemetic for controlling nausea and emesis by selectively interrupting the neurochemical signals arising from the Chemoreceptor Trigger Zone (CTZ) and the gut.

Regulatory References

  1. Ondansetron: MedlinePlus Drug Information

What side effects are possible with Amal?

Possible Side Effects and Safety Information for Amal

Official regulatory documents detail the known risks and safety considerations for Amal, categorized by severity and organ system. This information is derived from pre-approval clinical trials and post-marketing surveillance data, serving as the formal basis for the drug's safety profile.

Adverse Reaction Category Examples of Documented Reactions
Very Common (Affecting geq 1 in 10 patients) Headache, gastrointestinal discomfort (e.g., diarrhea, constipation), fatigue, and drowsiness.
Common (Affecting geq 1 in 100 to leq 1 in 10 patients) Dizziness, malaise, nausea, and vomiting.
Uncommon / Rare (Affecting leq 1 in 100 patients) Skin rash, fever, and certain extrapyramidal symptoms such as involuntary muscle contractions, agitation, or restlessness.

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions are defined as those that are life-threatening, result in hospitalization, or cause persistent disability. Key serious risks documented in official sources include a rare but potentially dangerous heart rhythm abnormality known as QT prolongation, which can lead to irregular heartbeat or syncope. Additionally, the drug has been associated with the risk of Serotonin Syndrome, a serious condition that can occur when Amal is taken alone or concurrently with other medicines that increase serotonin levels. Symptoms may involve mental status changes, fever, and muscle rigidity.

Safety-Related Restrictions and Monitoring

The product label includes specific safety restrictions and monitoring requirements. Caution is required in patients with pre-existing heart conditions, particularly those with a history of long QT syndrome or other cardiac rhythm disturbances. Careful monitoring for signs of Serotonin Syndrome is advised when used with other serotonergic agents. Population-specific considerations may apply, such as the need for dose adjustment in patients with renal or hepatic impairment, to mitigate the risk of adverse effects due to reduced clearance of the medicine from the body.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The official overdose information for Amal (Ondansetron) outlines documented clinical signs and the required emergency response.

Documented Overdose Presentations

In cases of excessive exposure, manifestations reported in regulatory documentation include transient visual disturbances (such as temporary loss of vision), severe constipation, and signs affecting the cardiovascular system, such as irregular heartbeat (including dose-dependent QT interval prolongation), hypotension, and fainting.

More serious, life-threatening outcomes reported in postmarketing surveillance include the development of a potentially fatal abnormal heart rhythm, Torsade de Pointes, and Serotonin Syndrome. Symptoms of Serotonin Syndrome can include profound changes in mental status (e.g., delirium, agitation), autonomic instability, and neuromuscular abnormalities (e.g., tremor, seizures).

Required Emergency Actions

Immediate medical attention or contact with a poison control center is required in cases of suspected overdose. Immediate emergency services must be called if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Management and Considerations

There is no specific antidote available for Ondansetron overdose; therefore, management is focused on providing appropriate symptomatic and supportive therapy. Due to the cardiac risk, continuous ECG monitoring is recommended in all suspected overdose cases and in patients with preexisting heart conditions or electrolyte abnormalities. Special attention is noted for patients with severe hepatic impairment, as reduced drug clearance may lead to prolonged drug exposure and increased toxicity risk.

Therapeutic Uses of Amal

The therapeutic role of Amal (Ondansetron) is applied across domains where additional symptomatic support is needed, focused on the control of symptoms related to heightened physiological activity, specifically nausea and vomiting. It is generally applied in situations where symptoms may intensify temporarily, providing supportive relief that helps patients cope more steadily with symptom fluctuations.

Control of Sickness in Oncology Support

Amal may be part of symptomatic management in conditions characterized by periods of heightened symptoms, which include the nausea and vomiting associated with certain medical procedures. This domain addresses symptoms that may appear suddenly, including acute manifestations and the subsequent delayed nausea and vomiting. The support provided helps ease the overall symptom burden, assisting patients during difficult symptomatic episodes by lessening distress associated with such phases.

It is commonly used to help with the symptomatic discomfort associated with nausea and vomiting that may be caused by chemotherapy or radiation protocols.

“The primary goal is offering symptomatic relief that helps patients cope more steadily during highly challenging treatment phases.”

Prevention of Postoperative Sickness

Amal is commonly used to help with the prevention or management of nausea and vomiting that may be triggered by general anesthesia and the post-surgical recovery process. Applied in scenarios where additional management of discomfort is required, this application contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability, which helps ease the symptom burden during post-procedure phases.


Quick Fact: Relief for Acute Emetic Symptoms

Amal is considered relevant in clinical settings that involve acute or disruptive symptom patterns, and may be part of symptomatic management when sickness symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Amal? (Ondansetron)

Absolute Prohibitions

Use of Amal is strictly contraindicated for patients concurrently receiving apomorphine, due to the risk of profound hypotension. It is also prohibited in individuals with a known hypersensitivity to ondansetron or other selective 5-HT3 receptor antagonists and must be avoided in those with congenital long QT syndrome due to the associated cardiac risks.

Population Restrictions and Cautions

Eligibility is restricted for patients with severe hepatic impairment (Child-Pugh score ge 10), where the total maximal daily dose must not exceed 8 mg. Use requires special caution and monitoring in individuals with risk factors for QTc prolongation (such as electrolyte abnormalities) and in patients at risk of progressive intestinal obstruction. Specific oral forms are restricted for individuals with hereditary disorders like galactose intolerance.

Age and Reproductive Eligibility

The medicine is approved for adult use in all labeled indications. Pediatric eligibility is established for CINV in children 6 months and older and for PONV in infants 1 month and older. Use is generally not recommended during the first trimester of pregnancy and while breastfeeding, based on official regulatory status concerning reproductive safety.

What should I know about interactions with other medicines?

Amal Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Amal (Ondansetron), based strictly on government regulatory documents.

Formally Prohibited Combinations

Co-administration of Amal is formally contraindicated with Apomorphine. This restriction is documented due to the risk of profound hypotension (severely low blood pressure) and loss of consciousness when these two medicines are used together.

Documented Pharmacokinetic Interactions

Amal is cleared from the body primarily by specific liver enzymes (CYP3A4, CYP2D6, CYP1A2). Co-administration with potent enzyme inducers, such as Phenytoin, Carbamazepine, and Rifampin, results in a significant increase in Amal's clearance, which leads to decreased blood concentrations of the medicine.

Pharmacodynamic Risk Enhancement

Caution and monitoring are advised when Amal is used with certain classes of medicines:

  • Serotonergic Drugs: Use with agents such as SSRIs, SNRIs, Tramadol, or Fentanyl may lead to a heightened risk of Serotonin Syndrome.
  • QT-Prolonging Agents: Amal itself affects the heart's electrical activity. Combining it with other medicines known to prolong the QT interval requires careful consideration due to an increased risk.

Population and Formulation Notes

The clearance of Amal is reduced in individuals with severe hepatic impairment, a factor noted in regulatory labeling. Additionally, the Orally Disintegrating Tablet (ODT) formulation of Amal contains phenylalanine and carries a specific note for patients with Phenylketonuria (PKU).

Mechanism of Action

Selective Blockade of the Serotonin 5-HT3 Receptor

This domain explains the drug's primary molecular action: its function as a selective antagonist that competitively binds to the 5-HT3 receptor. By occupying the receptor site, the drug prevents the endogenous neurotransmitter serotonin (5-HT) from binding and initiating the rapid flow of ions across the neuronal cell membrane, initiating the interruption of afferent signaling toward the Vomiting Center.

Dual Interruption of the Emetic Reflex Pathway

The mechanism exerts a concurrent central and peripheral physiological influence by acting both peripherally on the vagal afferent nerves in the gastrointestinal tract and centrally within the Chemoreceptor Trigger Zone (CTZ). This dual blockade facilitates the interruption of emetic signals at both peripheral and central sites, ensuring the Medullary Vomiting Center receives reduced excitatory input.

Mechanistic Constraints of 5-HT3 Antagonism

The high specificity of the drug’s mechanism means its physiological effect is limited to pathways dominated by serotonergic signaling. The mechanism’s action is specific to serotonergic signaling, which dictates its constraint in physiological contexts where other mediators drive the emetic response, such as those governing vestibular pathways (e.g., histamine or acetylcholine pathways).

Dosage and Administration Information

How Amal is Used

Amal (Ondansetron) is administered through specific parameters that define the route, dosage, and timing. The medication is available for Oral use (tablets, solution, and orally disintegrating tablets) and for Parenteral use (intravenous or intramuscular injection).

Administration is typically prophylactic, meaning the initial dose is given before the procedure to establish protection. For chemotherapy-induced nausea and vomiting (CINV), the starting dose is administered either 30 minutes before the start of chemotherapy, or immediately prior to surgery for postoperative nausea and vomiting (PONV). The oral dose for highly emetogenic chemotherapy (HEC) is a single dose of 24 mg, while the standard intravenous dose for PONV prophylaxis is a single 4 mg injection.


Dosage Schedules and Conditions

For ongoing symptom management following moderately emetogenic chemotherapy (MEC), oral dosing usually continues for one to two days on a twice-daily (8 mg every 12 hours) regimen. The method of administration is conditioned by the dose size. Intravenous doses greater than 8 mg must be diluted and administered as a controlled 15-minute infusion to ensure proper delivery. Oral forms may be taken with or without food. For specific patient populations, such as those with severe hepatic impairment, the total daily dose does not exceed 8 mg for either the oral or intravenous route.

Recent Clinical Evidence

The investigational therapeutic agent referred to as Amal encompasses multiple small-molecule drug candidates, primarily focused on neurological and oncological conditions. Recent clinical research and development programs are multifaceted, with agents targeting distinct mechanisms of action across different disease states.

Neurological Focus: Autism Spectrum Disorder (ASD) and Alzheimer's Disease (AD)

A lead compound, a nitric oxide (NO) inhibitor, has been a central focus for neurodevelopmental and neurodegenerative disorders. The foundational science for this agent suggests a link between the abnormal overproduction of nitric oxide in the brain and the underlying pathology of conditions like ASD. Pre-clinical models indicated that suppressing NO production may help reverse neuronal and behavioral deficits.

  • Phase 1 Trials: Following the receipt of Orphan Drug Designation for Phelan-McDermid Syndrome (a subtype of ASD), Phase 1 clinical trials for this oral small-molecule nitric oxide inhibitor are anticipated to begin in 2026. The initial goal is to establish safety and tolerability, with subsequent development planned for ASD and indications such as Alzheimer’s disease.

Oncology Focus: Therapeutic Cancer Vaccines

Clinical development programs for cancer indications involve a distinct class of agents, specifically therapeutic cancer vaccines built on a proprietary immunization platform. These vaccines are designed to elicit a strong and targeted anti-tumor immune response.

Vaccine Candidate Indication Phase Status
ATP128 (KISIMA-01) Stage IV Colorectal Cancer Phase 1/2
ATP150/ATP152/ATP162 (KISIMA-02) Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1b (Ongoing)

The KISIMA-01 trial is evaluating the vaccine's safety, tolerability, and preliminary efficacy in combination with a checkpoint inhibitor in patients with metastatic colorectal cancer. The ongoing KISIMA-02 study is a first-in-human trial investigating a combination regimen for PDAC, seeking to determine the optimal dose and safety profile of the novel vaccine components alongside a PD-1 inhibitor.

Key Studies & References

  1. NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
  2. Haitham Amal: targeting autism spectrum disorder, Alzheimer's disease, and glioblastoma with small-molecule drugs - Advanced Science News
  3. NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders
  4. ATP128 vaccine with ezabenlimab promotes antigen-specific immune responses in stage IV colorectal cancer in the KISIMA-01 Phase 1b trial
  5. A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma (KISIMA-02) - NCI
  6. KISIMA® cancer vaccine | InOncology – Boehringer Ingelheim

Frequently Asked Questions (FAQ)

Common questions about Amal (FAQ)

Q: How long does it typically take to see any initial effects from Amal?

Official prescribing information indicates that Amal (Ondansetron) is quickly absorbed through the digestive tract when taken orally. Initial anti-nausea effects are often noted within 30 minutes after taking an oral dose.

Q: How does Amal compare generally to similar drugs, without saying which is better?

Amal is classified as a selective 5-HT3 receptor antagonist. This mechanism specifically targets the blockade of serotonin (5-HT) signals related to the vomiting reflex, a characteristic that differentiates it from some older, broader anti-nausea medications.

Q: Are there any long-term health risks associated with taking Amal?

The drug's official warnings, such as the potential for QT prolongation (a change in the heart's electrical rhythm), are primarily associated with its use, which is typically for short-term courses. Risks associated with long-term, chronic use beyond the standard approved period are not fully detailed in the standard prescribing information.

Q: Can Amal affect my mood or mental clarity?

Official documents list effects on the nervous system and psychiatric health. These documented effects include drowsiness, dizziness, and anxiety, and in rare or uncommon reports, agitation or disturbances in behavior have been noted.

Q: What kind of studies have been done on the long-term effectiveness of Amal?

The drug's regulatory approval is supported by clinical trials that established its use in preventing nausea and vomiting associated with chemotherapy, radiation therapy, and surgical procedures. These foundational studies documented its utility in these acute settings.

Q: What happens if you suddenly stop taking Amal?

Because the medicine is primarily prescribed for short-term use (typically 1–2 days) for its approved indications, official regulatory information generally does not detail a formal cessation or withdrawal syndrome upon stopping the medication.

Q: Is Amal a new medication or has it been around for a while?

The active ingredient in Amal, Ondansetron, is an established medicine. It was originally approved for medical use in 1990, meaning it has been available for clinical use for several decades.

Q: Do you have to take Amal forever, or can you stop after a certain time?

For its approved uses, such as preventing nausea and vomiting from chemotherapy or surgery, the medicine is typically taken for short periods, often only one to two days following the initial procedure or treatment. The expectation of use is generally temporary, not chronic.

Q: Can Amal be taken with common over-the-counter pain relievers like ibuprofen?

Official drug interaction studies do not generally list a specific pharmacokinetic or pharmacodynamic interaction with common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.

Q: Are there any specific foods or drinks (like grapefruit or alcohol) that interact with Amal?

Official labeling does not contain specific warnings regarding interactions with alcohol or grapefruit juice. Regulatory documents indicate that the oral forms of the medicine may be taken with or without food.

Q: Is it possible to take Amal on an 'as-needed' basis?

While initial administration is often prophylactic (preventative) and scheduled, official guidance indicates the drug is also used on an 'as-needed' basis (often referred to as PRN) to manage symptoms that occur despite initial preventative treatment.

Q: Do I need a special prescription or authorization to get Amal?

Yes, Amal (Ondansetron) is classified as a prescription-only medicine (POM) and is not available for purchase over the counter. It is not currently listed as a controlled substance.

Q: Has Amal received warnings or black box labels in certain countries?

Official warnings have been issued by regulatory bodies, such as the US FDA, regarding the risk of a heart rhythm abnormality known as QT prolongation, especially when a high single intravenous dose was used (which is now restricted). However, the medicine does not carry the US FDA's strongest 'Black Box Warning'.

Q: Does the time of day matter when taking Amal?

The timing of the dose is determined by the specific event it is meant to prevent, such as administering it before chemotherapy or surgery, rather than a particular time of day (morning or evening).

Q: Is Amal known to cause any issues with vision or hearing?

Official clinical data documents that transient visual disturbances (like blurred vision) are reported as common or uncommon side effects. Permanent vision or hearing issues are not listed in the most frequent adverse reaction categories.

Q: Does Amal affect sleep patterns?

While drowsiness is a documented common effect, official reports also list 'sleep disturbance' (insomnia or changes in sleep quality) as a common or uncommon adverse reaction.

How should Amal be stored and disposed of?

How to Store and Dispose of Amal?

Storage & Stability Requirement Official Regulatory Statement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions.
Protection & Handling Keep the product in its original container to protect it from light and moisture. Do not freeze the product.
Post-Opening Stability If applicable, any unused portion of the product must be discarded within [X days/weeks] after first opening or reconstitution.
Child Protection Must be stored out of the sight and reach of children to prevent accidental ingestion or misuse.

Disposal Protocol

Unused or expired Amal must be disposed of in a manner that prevents diversion and environmental contamination, as defined by official regulatory guidelines. The preferred method is typically a drug take-back program or a community disposal location. If these options are not readily available, follow the FDA's instructions for mixing the medicine with an undesirable substance (like coffee grounds or cat litter), sealing it in a plastic bag, and discarding it in household trash. Only medicines on the official 'flush list' should be flushed down the toilet when take-back options are unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amal found in:

A-Z Index: